AXSOME THERAPEUTICS, INC. (AXSM) Current Ratio
- Current ratio · latest quarter: Value 1.43×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.43× | Current assets / current liabilities. $656.57M ÷ $460.45M ≈ 1.43× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 656.57M USD | Assets, Current |
| Current obligations | 460.45M USD | Liabilities, Current |
| Cash and equivalents | 319.85M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 277.46M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 37.88M USD | Inventory, Net |
| Payables | 78.97M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 70.00M USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $656.57M | $460.45M | $319.85M | (m) | $277.46M | $37.88M | $78.97M | $70.00M | 1.43× |
| 2026-03-31 | $611.21M | $439.21M | $305.11M | (m) | $251.06M | $31.52M | $106.70M | $70.00M | 1.39× |
| 2025-12-31 | $588.99M | $378.84M | $322.93M | (m) | $224.46M | $27.94M | $65.54M | $70.00M | 1.55× |
| 2025-09-30 | $565.34M | $360.29M | $325.27M | (m) | $196.51M | $23.77M | $54.23M | $70.00M | 1.57× |
| 2025-06-30 | $536.62M | $342.10M | $303.02M | (m) | $198.82M | $18.44M | $91.63M | $70.00M | 1.57× |
| 2025-03-31 | $494.63M | $243.91M | $300.91M | (m) | $161.40M | $16.32M | $85.66M | (m) | 2.03× |
| 2024-12-31 | $485.06M | $230.10M | $315.35M | (m) | $142.00M | $15.73M | $72.00M | $0.00 | 2.11× |
| 2024-09-30 | $479.11M | $196.19M | $327.34M | (m) | $124.10M | $14.27M | $64.25M | (m) | 2.44× |
| 2024-06-30 | $463.03M | $186.57M | $315.66M | (m) | $120.34M | $15.22M | $61.34M | (m) | 2.48× |
| 2024-03-31 | $460.49M | $144.05M | $331.44M | (m) | $101.43M | $15.58M | $53.79M | (m) | 3.20× |
| 2023-12-31 | $504.26M | $138.85M | $386.19M | (m) | $94.82M | $15.13M | $40.68M | (m) | 3.63× |
| 2023-09-30 | $511.76M | $114.66M | $416.56M | (m) | $78.42M | $9.98M | $29.10M | (m) | 4.46× |
| 2023-06-30 | $519.69M | $114.97M | $437.11M | (m) | $67.41M | $9.25M | $42.96M | (m) | 4.52× |
| 2023-03-31 | $304.45M | $100.65M | $246.51M | (m) | $44.79M | $7.94M | $35.77M | (m) | 3.02× |
| 2022-12-31 | $245.64M | $96.56M | $200.84M | (m) | $37.70M | $4.32M | $38.60M | (m) | 2.54× |
| 2022-09-30 | $252.38M | $60.28M | $227.52M | (m) | $20.30M | $2.10M | $12.84M | (m) | 4.19× |
| 2022-06-30 | $103.98M | $42.57M | $73.39M | (m) | $16.17M | $10.32M | $19.43M | (m) | 2.44× |
| 2022-03-31 | $86.83M | $24.55M | $84.71M | (m) | (m) | (m) | $12.60M | (m) | 3.54× |
| 2021-12-31 | $86.52M | $23.07M | $86.47M | (m) | (m) | (m) | $13.15M | (m) | 3.75× |
| 2021-09-30 | $115.02M | $24.71M | $114.62M | (m) | (m) | (m) | $13.38M | (m) | 4.66× |
| 2021-06-30 | $141.65M | $22.86M | $141.22M | (m) | (m) | (m) | $11.61M | (m) | 6.20× |
| 2021-03-31 | $165.04M | $21.68M | $164.66M | (m) | (m) | (m) | $14.62M | (m) | 7.61× |
| 2020-12-31 | $184.02M | $23.44M | $183.88M | (m) | (m) | (m) | $13.50M | (m) | 7.85× |
| 2020-09-30 | $203.27M | $20.34M | (m) | (m) | (m) | (m) | $11.32M | (m) | 9.99× |
| 2020-06-30 | $190.82M | $23.00M | (m) | (m) | (m) | (m) | $9.36M | $6.55M | 8.30× |
| 2020-03-31 | $197.62M | $26.10M | (m) | (m) | (m) | (m) | $12.19M | $4.57M | 7.57× |
| 2019-12-31 | $220.38M | $24.49M | $219.97M | (m) | (m) | (m) | $10.94M | $2.60M | 9.00× |
| 2019-09-30 | $44.24M | $18.51M | (m) | (m) | (m) | (m) | $9.45M | $648.52K | 2.39× |
| 2019-06-30 | $54.57M | $13.07M | (m) | (m) | (m) | (m) | $6.14M | $2.16M | 4.18× |
| 2019-03-31 | $43.76M | $7.71M | (m) | (m) | (m) | (m) | $3.43M | $535.77K | 5.68× |
| 2018-12-31 | $15.22M | $10.82M | (m) | (m) | (m) | (m) | $3.69M | $3.29M | 1.41× |
| 2018-09-30 | $15.94M | $10.94M | (m) | (m) | (m) | (m) | $4.17M | $3.29M | 1.46× |
| 2018-06-30 | $21.54M | $9.53M | (m) | (m) | (m) | (m) | $3.18M | $3.28M | 2.26× |
| 2018-03-31 | $27.75M | $9.42M | (m) | (m) | (m) | (m) | $3.87M | $3.28M | 2.95× |
| 2017-12-31 | $35.30M | $12.18M | (m) | (m) | (m) | (m) | $3.44M | $3.27M | 2.90× |
| 2017-09-30 | $32.42M | $8.40M | (m) | (m) | (m) | (m) | $2.94M | $2.72M | 3.86× |
| 2017-06-30 | $38.84M | $8.21M | (m) | (m) | (m) | (m) | $4.04M | $1.90M | 4.73× |
| 2017-03-31 | $46.20M | $8.36M | (m) | (m) | (m) | (m) | $4.74M | $1.08M | 5.53× |
| 2016-12-31 | $38.00M | $7.17M | (m) | (m) | (m) | (m) | $4.08M | $269.16K | 5.30× |
| 2016-09-30 | $34.75M | $6.74M | (m) | (m) | (m) | (m) | $3.87M | (m) | 5.16× |
| 2016-06-30 | $39.92M | $5.10M | (m) | (m) | (m) | (m) | $3.04M | (m) | 7.82× |
| 2016-03-31 | $45.07M | $3.91M | (m) | (m) | (m) | (m) | $1.83M | (m) | 11.51× |
| 2015-12-31 | $49.03M | $2.63M | (m) | (m) | (m) | (m) | $1.89M | (m) | 18.63× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |